BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25970720)

  • 1. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
    Maier H; Hehemann K; Vieth M
    Cesk Patol; 2015; 51(2):87-8. PubMed ID: 25970720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
    Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY; Yang B; Shi D; Li H; Zou Z; Shi XY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D; Hill MD
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
    Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
    [No Abstract]   [Full Text] [Related]  

  • 7. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA; Nuñez JF; Domínguez-Gil A;
    Drugs Aging; 2009; 26(7):617-26. PubMed ID: 19655828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eprosartan: a review of its use in the management of hypertension.
    Robins GW; Scott LJ
    Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
    Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eprosartan.
    McClellan KJ; Balfour JA
    Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eprosartan: a review of its use in hypertension.
    Plosker GL
    Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In diarrhea of unknown origin also think of olmesartan!].
    Storr M
    MMW Fortschr Med; 2015 Mar; 157(4):34. PubMed ID: 25743974
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and tolerability of eprosartan.
    Gavras I; Gavras H
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):102S-107S. PubMed ID: 10213529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ; Rupp H
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
    Shusterman NH
    Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sprue-like enteropathy linked to olmesartan.
    Campos Ruiz A; Urtasun Arlegui L; Marra-López Valenciano C
    Rev Esp Enferm Dig; 2016 May; 108(5):292-3. PubMed ID: 26925975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study].
    Nüdling S; Kahner-Gröne S; Köneke D; Marggraf K; Palissa H
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():96-101. PubMed ID: 21595153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.